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Abstract 
 
Trigeminal neuralgia (TN) is a rare neuropathic facial pain disorder.  Two forms of TN, 
classical TN (CTN) and atypical TN (ATN), are reported and probably have different 
aetiologies.  The aim of the present study was to evaluate the functional integrity of the 
diffuse noxious inhibitory controls (DNIC) in (1) a group of patients with classical 
trigeminal neuralgia (CTN), (2) a group of patients with atypical trigeminal neuralgia 
(ATN), and (3) a group of healthy controls in order to determine if a descending pain 
modulation deficit could participate in the pathophysiology of TN pain.  DNIC responses 
of 14 CTN patients, 14 ATN patients and 14 healthy controls were obtained by 
comparing thermode-induced facial heat pain scores before and after activating DNIC.  
DNIC was triggered using a standard counter-irritation paradigm (i.e., immersion of the 
arm in painfully cold water).  General sensitivity to pain was also evaluated by measuring 
mechanical pain thresholds over 18 points located outside the trigeminal territory.  
Healthy participants and CTN patients showed a 21% and 16% reduction in thermode-
induced pain following the immersion, respectively (all p-values <.01), whereas ATN 
patients experienced no change (p=.57).  ATN patients also had more tender points 
(mechanical pain thresholds < 4.0 kg) than CTN and healthy controls (all p-values < .05).  
Taken together, these results suggest that the underlying physiopathology differs between 
CTN and ATN and that a deficit in descending inhibition may further contribute to the 
pain experienced by patients with ATN. 
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Introduction 
Trigeminal neuralgia (TN) is a rare neuropathic facial pain disorder affecting the 
fifth cranial nerve.  Two forms of TN, classical TN (CTN) and atypical TN (ATN), are 
reported [55].  Patients with CTN experience sharp, paroxystic pain lasting from a few 
seconds to two minutes, whereas ATN patients report (in addition to these pain 
paroxysms) a more constant and diffuse type of pain which is, clinically, often more 
difficult to treat [55;56].  It should be noted that differentiation between CTN and ATN is 
based on symptom constellation (i.e. presence or absence of constant pain between 
paroxysms).  This categorization should be distinguished from other commonly proposed 
classifications such as those which divide TN into idiopathic or symptomatic based 
simply on aetiology [8;16]. 
Even though TN was first described centuries ago, its underlying pathophysiology 
remains poorly understood [7;39].  Microvascular compression of the trigeminal nerve 
continues to be the most proposed cause of TN [31].  However, the latter cannot entirely 
explain TN as neuroimaging and post-mortem evidence demonstrate that:  (1) 
microvascular compression is absent in many patients with TN [3;20;43], and (2) many 
people with a microvascular compression do not report facial pain [2;18;23]. 
Some authors have suggested that a deficit in the functional integrity of 
endogenous pain modulating responses could contribute to the pain experienced by TN 
patients [42].  Such a premise comes, for the most part, from the work of Fromm and 
colleagues [13] who showed, using animal models, that the anticonvulsant drugs that 
effectively treat TN (carbamazepine, baclofen, phenytoin) increased endogenous pain 
modulating responses, whereas anticonvulsants that were ineffective in treating TN 
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(phenobarbital) did not affect endogenous pain modulating responses.  These 
observations gave rise to the hypothesis that a failure of inhibitory mechanisms may play 
an important role in the pathogenesis of TN, a hypothesis that has never been formerly 
tested. 
Endogenous pain modulating deficits as a possible cause of chronic pain is not 
specific to TN and has in fact been postulated and validated in a variety of other painful 
disorders including fibromyalgia (FM), tension-type headache (TTH), migraine, and 
temporomandibular disorders (TMD)[21;25;30;40].  More specifically, these studies 
revealed that FM, TTH, migraine and TMD patients all showed a deficit of the diffuse 
noxious inhibitory controls (DNIC), a descending pain modulating mechanism 
originating in the brainstem and exerting a powerful and diffuse analgesic effect [27].  
These findings clearly remind the clinician and the researcher that painful conditions 
should not only be seen as the end result of increased nociception but also, in some 
situations, as the product of impaired inhibitory processes [11]. 
The primary objective of this study was to evaluate the functional integrity of the 
DNIC system in a group of healthy controls, a group of CTN patients and a group of 
ATN patients.  A second objective was to compare the strength of DNIC in the three 
groups.  Finally, a third and last objective was to determine if CTN and ATN patients 
display evidence of increased tenderness in body regions not innervated by the fifth 
cranial nerve, thus testing the possibility that an eventual DNIC deficit would influence 
pain sensitivity beyond the trigeminal territory. 
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Methods 
Participants 
Thirty patients diagnosed with TN (15 CTN and 15 ATN) and 15 healthy controls 
participated in the study (all participants  40 years old).  All TN patients were recruited 
among patients referred to the Gamma-knife surgery (GKS) clinic of the Sherbrooke 
University Hospital. Diagnosis of idiopathic TN was confirmed by a neurosurgeon (DM, 
JB or BK) using the International Classification of Headache Disorders criteria [19].  
Patients with atypical facial pain (a distinct condition characterized by unexplained facial 
pain but without paroxysmal attacks [12;19]) were excluded from the present study.  
Patients with symptomatic TN (e.g. TN secondary to multiple sclerosis or with symptoms 
suggesting post-herpetic or deafferentation pain syndromes were also excluded.  No 
patients showed evidence of tactile, thermal or pricking hypoesthesia.  There was no sign 
of dysesthesia, hyperesthesia or allodynia.  In addition to a conventional neurologic 
examination, every participant was examined with a magnetic resonance imaging (MRI) 
to rule out neuronal damage. 
Differentiation between CTN and ATN was made by the experimenter (GL) and 
by the neurosurgeons (DM, JB and BK) before psychophysical testing using the criteria 
proposed by Zakrzewska [55].  Specifically, patients with painful paroxysms but who 
were pain free between the attacks were classified as CTN patients.  In contrast, patients 
who reported painful paroxysms with the presence of a dull, burning, continuous 
background pain in between the attacks were classified as ATN patients.  These 
differentiation criteria have been used previously both for clinical and experimental 
purposes [36;55;56]. 
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Healthy controls were recruited through local ads and were all community-
dwelling individuals.  They all had good general health and none suffered from any 
painful conditions with the exception of three participants who reported minor 
osteoarthritic pain.  An attempt was made to age and sex match healthy controls with 
patients.  Every participant was asked to refrain from using short term analgesics two 
hours before testing and from drinking coffee and smoking cigarettes six hours before 
testing.  TN patients were also asked to stop all pain medications for a period of 24 hours 
before their appointment.  Patients’ characteristics are listed in Table 1 and 2. 
The experiment took place at the Clinical Research Centre of the Sherbrooke 
University Hospital (Sherbrooke, Quebec, Canada).  The entire experimental session 
lasted about 120 minutes.  The local Institutional Ethics Committee approved the study’s 
procedures and each participant provided informed consent before participation. 
 
Trigeminal thermode testing 
Participants were seated comfortably in a reclining chair.  A pre-testing session 
was first provided where three painful thermal stimulations (46, 47 and 48 degrees 
Celsius) were applied for 5 seconds (preceding ramp-up time of 15 seconds, interval 
between stimuli of 30 seconds) on the trigeminal affected area using a 1 cm2 Peltier-type 
thermode (Medoc, Advanced Medical Systems, Minneapolis).  This pre-testing session 
allowed our participants to become familiar with the experimental protocol and helped 
reduce stress and anxiety.  When more than one trigeminal division was affected, the 
thermode was placed over the most affected division.  This resulted in 2 patients being 
tested on the V1 territory, 18 patients on the V2 territory and 10 patients on the V3 
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territory.  Healthy controls were also exposed to the same three thermal stimulations as 
those provided to TN patients and on regions which matched (in location and proportion) 
those of TN patients (9 healthy controls tested on the V2 territory and 6 healthy controls 
tested on the V3 territory).   
Participants were then given a 5 minute rest period before the experimental test 
began.  All participants were told that the stimulation used during testing would be 
similar to the ones experienced during pre-tests, and that they would have to evaluate the 
intensity of the pain using a 0 to 100 numerical rating scale (NRS) (0 = no pain, 100= 
intolerable pain) during the interval between stimuli.  Testing then began using the same 
protocol (trigeminal distribution, temperatures, ramp-up time, interval between stimuli) 
employed during the pre-test.  At all times during the pre-testing and testing sessions, 
great care was taken to avoid stimulation of TN trigger zones. 
 
Arm Cold Pressor Test (DNIC activation) 
Participants were then asked to immerse their right arm for 5 minutes in a bath of 
circulating cold water maintained at 10 degrees Celsius.  This procedure, commonly 
known as the cold pressor test (CPT), was used to trigger descending inhibitory 
responses, with previous studies showing that it is a reliable and effective way of 
triggering such responses [45].  Every 30 seconds, patients rated their immersion-induced 
pain using the same numerical scale that was used during thermode testing (0= no pain; 
100 = intolerable pain).  Subjects were instructed to remove their arm if the stimulation 
became too painful or uncomfortable.  Participants who were unable to tolerate the 
stimulation for more than 2 minutes were excluded from all analyses.  This occurred in 
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only three participants (1 CTN, 1 ATN and 1 healthy control; n after exclusions = 42).  
Imposing a minimum of 2 minutes of immersion time ensured that the CPT was 
sufficiently painful to trigger inhibitory responses [45].  Most of the remaining 
participants tolerated the CPT for the entire 5 minutes (long immersion group) however 9 
of them (3 CTN, 5 ATN and 1 healthy) removed their arm between 2 and 5 minutes of 
immersion time (short immersion group).  A preliminary Kruskall-Wallis analysis 
conducted to ensure that long and short immersions produced similar DNIC effects 
showed that immersion time did not influence DNIC effects (p=.21), at least for 
situations where immersions lasted more than 2 minutes. 
Immediately after the CPT, subjects were asked to remove their arm from the cold 
water and the thermode test was repeated one last time over the same region as the one 
previously tested.  The percentage difference in thermode pain scores obtained prior to 
and following the immersion procedure constitutes the metric of the inhibitory response.   
 
Mechanical pain thresholds 
In order to evaluate pain sensitivity outside the territory of the trigeminal nerve, 
mechanical pain thresholds were determined using a standard pressure algometer (FGE-
100X, Shimpo Instruments, Illinois).  To ensure standardisation, and because we wanted 
to measure pain sensitivity over both upper and lower quadrants of the body, measures 
were taken over the 18 tender points used to diagnose FM according to the American 
College or Rheumatology [51].  Mechanical pain thresholds less than 4.0 kg were 
considered “positive” (abnormally sensitive), and the total number of positive points were 
summed for each participant.  Importantly, mechanical pain thresholds were obtained 
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before thermode testing began, at the onset of the experiment, so that none of our 
experimental tests affected pressure values. 
 
Statistical analysis 
Because of the relatively small number of subjects included in this study and 
because visual inspection of the histograms did not allow us to assume that the data were 
normally distributed, non-parametric tests were used.  Specifically, the Wilcoxon Signed-
Rank Test (within-subject analysis) was used to compare thermode pain scores before 
and after CPT.  This allowed us to evaluate the functional integrity of the DNIC system 
for each group (Objective 1).  Alternately, between-subject analyses (Mann-Whitney Test 
and Kruskall-Wallis Test) were used to compare (i) the percentage change in pain scores 
before and after the CPT, and (ii) the number of tender points between the three different 
groups.  This allowed us to meet our second and third objectives which were to determine 
(i) if there was a difference in the strength of DNIC between the three groups of 
participants, and (ii) if CTN and ATN patients showed evidence of increased tenderness 
in body regions not innervated by the fifth cranial nerve when compared with healthy 
participants.  Differences were considered to be significant if p < 0.05 was obtained. 
 
Results 
Baseline thermode measures 
Facial pain scores obtained prior to CPT for the different temperatures (46, 47 and 
48º C) are reported in Table 3.  As it can be seen from the table, higher thermode 
temperatures were rated as more painful than lower thermode temperatures in all three 
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groups.  Table 3 also shows that the three groups of participants had comparable levels of 
baseline pain, although there was a slight tendency for both CTN and ATN patients to 
report higher scores than healthy controls.  Between group differences reached statistical 
significance only for the 47º C stimulation condition, revealing higher pain scores for 
CTN and ATN patients than for healthy controls. 
 
Immersion-induced pain 
Every participant experienced the CPT as painful (all NRS  20).  Kruskall-Wallis 
Test conducted to test for group differences in average CPT pain revealed a group effect 
(p=.02) , with Mann-Whitney post-hoc tests showing that both CTN and ATN patients 
had higher pain scores than healthy controls (CTN = 73 ± 25, ATN = 69 ± 27, healthy 
controls = 47 ± 25; all p-values < .05).   There was no difference between the CTN and 
ATN group (p=.66). 
 
Functional integrity of the DNIC system 
In order to simplify data presentation and because statistical analyses showed no 
effect of thermode temperature on DNIC results, facial pain ratings obtained at each of 
the three stimulation levels (46, 47 and 48 degrees Celsius) were averaged and this 
average was used in all subsequent analyses.  Average thermode pain scores obtained 
before and after CPT showed that DNIC efficacy varied among the three groups.  
Specifically, Wilcoxon Signed-Rank tests revealed that both healthy controls and CTN 
patients experienced a reduction in thermal pain following immersion in cold water (all 
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p-values <.01), whereas there was no change for patients with ATN (p=.57) (see Figure 
1). 
 
Strength of the DNIC effect 
In order to directly test for group differences in DNIC efficacy, percentages of 
pain reductions were calculated for each group [pain reduction = (pain before CPT – pain 
after CPT)/ pain before CPT * 100] and compared using a Kruskall-Wallis Test.  Healthy 
controls, CTN patients and ATN patients experienced a 21%, 16% and 1% reduction in 
pain following CPT, respectively, with the Kruskall-Wallis test showing a significant 
difference between the three groups.  Mann-Whitney post-hoc tests revealed that there 
was a difference in terms of percentage of pain reduction between the ATN and CTN 
group (p=.02) and between the ATN and healthy control group (p=.03) but not between 
the CTN and healthy control group (p=.38).  Differences between each group in terms of 
percentages of pain reductions are illustrated in Figure 2. 
Additional analyses were performed to determine if thermode laterality (i.e. if the 
thermode was placed ipsilaterally or contralaterally to the arm used for CPT) affected the 
magnitude of the DNIC response.  Mann Whitney Tests for all groups showed no effect 
of thermode placement on DNIC strength (all p-values >.22). 
 
Mechanical pain thresholds 
Because of time constraints, measures of mechanical pain thresholds could not be 
obtained from two participants (one CTN and one ATN patients).  Results obtained from 
the remaining 40 participants revealed that there was a difference between the three 
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groups for the number of tender points (healthy controls = 4 ± 3, CTN patients = 6 ± 3, 
ATN patients = 10 ± 4; p<.01).  Post-hoc analysis using Mann-Whitney Tests revealed 
that ATN (p<.001), but not CTN patients (p=.09) had more tender points than healthy 
control.  Comparison between ATN and CTN patients was also significant, with ATN 
patients exhibiting a higher number of tender points (p<.05).  Interestingly, when 
considering the criteria of the American College of Rheumatology (ACR) for a positive 
diagnosis of FM (i.e. tenderness at 11 or more sites [51]) 38% of the ATN patients would 
have met the criteria for FM compared with 15% for CTN patients and 0% for healthy 
participants. 
 
Previous TN surgery 
 Because some of the patients tested had previous TN surgery, we performed 
exploratory analyses to determine whether there were any differences between patients 
with and without previous neurosurgical intervention.  Mann-Whitney Tests for both 
CTN and ATN patients showed that there were no differences between patients with and 
without previous TN surgery for all dependent variables of interest (baseline facial pain 
ratings, DNIC strength, number of tender points, McGill Pain Questionnaire score; all p-
values >.14). 
 
Discussion 
Main findings 
In the present report, we sought to determine if TN could be associated with a 
deficit of the DNIC system.  Our results showed that ATN, but not CTN patients, had a 
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reduced DNIC effect compared to healthy controls.  Healthy participants and CTN 
patients showed a 21% and 16% reduction in pain following CPT, respectively, whereas 
ATN patients experienced only a 1% change.  The idea that a deficit of the endogenous 
modulating system could contribute to the pain experienced by TN patients is not new 
and as been suggested by various authors [13;42].  Until today, however, this hypothesis 
was never formally tested, and so remained purely hypothetical.  The present study 
provides, to our knowledge, the first evidence of a deficit of the endogenous pain 
modulating system in ATN patients. 
Traditionally, evaluation of the DNIC system has been made by comparing a first 
set of nociceptive measures obtained at baseline with a second set of nociceptive 
measures obtained during a conditioning stimulus [26;35].  Alternatively, other studies 
have employed experimental paradigms in which DNIC evaluation was made by 
comparing nociceptive measures obtained before to nociceptive measures obtained after 
the conditioning stimulus [24;45].  Testing DNIC by applying the conditioning and test 
stimuli successively is possible because DNIC’s analgesic effect persists beyond the 
application and removal of the conditioning stimulus [5;15;37;47;50].  Although 
simultaneous application of the test and conditioning stimuli probably yield higher DNIC 
effects than sequential paradigms (notably because DNIC effects fade with time) [37], the 
latter have the advantage of diminishing the potential for distraction-induced confounds.  
This is particularly relevant since a strong, painful conditioning stimulus likely has 
attention-grabbing properties. 
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Mechanical pain thresholds 
Since DNIC effects are diffuse by nature, one could expect that the consequences 
of a DNIC deficit would not solely be restricted to the region of the face.  The fact that 
ATN patients showed increased tenderness in body regions not innervated by the 
trigeminal nerve supports the hypothesis of a general and diffuse inhibitory deficit.  It 
remains unclear, however, why ATN patients predominantly report clinical symptoms 
that are circumscribed to the trigeminal territory.  A possible explanation might be that 
DNIC deficit will evolve through time to eventually produce pain across various regions 
of the body.  In this manner, ATN patients, if assessed longitudinally, may eventually 
report painful symptoms not circumscribed to the face.  It is also important to note that 
we did not explicitly (and comprehensively) assess pain complaints beyond the 
trigeminal territory. 
This association between facial pain and widespread pain has been shown in 
previous studies[17;44;46].  For instance, Hagberg et al.[17] reported that the prevalence 
of musculoskeletal pain in various parts of the body was higher in women suffering from 
craniomandibular disorders than in women sampled from the general population.  
Similarly, Sipilä et al.[44] showed that, compared with control subjects, subjects with 
TMD and other undiagnosed facial pain disorders had significantly more pain outside the 
facial area and significantly more painful fibromyalgia points.  Although we did not 
evaluate pain complaints outside the trigeminal territory, our findings of increased tender 
points in ATN patients are coherent with the results of Hagberg et al.[17] and Sipilä et 
al.[44]. 
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Interestingly, the large number of positive tender points found in ATN patients 
suggests that a parallel can be drawn between ATN and FM.  In fact, our results indicate 
that up to 38% of ATN patients would have met the ACR defined criteria for FM 
(compared with 15% for CTN patients and 0% for healthy participants).  These 
observations are coherent with the results of other studies who have suggested some 
important overlap between facial pain conditions and FM [1;4;9;38].   They are also 
especially compelling if we consider that FM (like ATN) has been associated with a 
descending inhibitory deficit [21;25].  
Perhaps another resemblance between ATN and FM is the limited success that 
appears to be obtained following conventional therapeutic interventions.  For instance, 
several authors have shown that the efficacy of microvascular decompression (MVD) and 
GKS was decreased in ATN patients when compared with CTN patients [6;14;28;29;48].  
This resistance to treatment can probably be explained by the fact that surgical 
interventions will have little to no effect on the functional integrity of descending 
inhibitory circuits.  Additional therapeutic interventions aimed at rekindling inhibitory 
responses may yield more promising results than surgical management alone [33;34;49]. 
A recent study by Obermann et al. [36] found that ATN patients had larger pain-
related evoked potentials (PREP) amplitudes following electrical stimulation of the 
trigeminal nerve than CTN patients.  Because there was no difference between CTN and 
ATN patients for the nociceptive blink reflex, Obermann et al. [36] concluded that the 
increased PREP amplitudes probably reflected global supraspinal adaptation mechanisms 
associated with the development of chronic constant pain in the group of ATN patients.  
These adaptations could include increased activity of the excitatory mechanisms (e.g. 
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sensitization) and/ or decreased activity of the inhibitory mechanisms [34].  Without 
excluding the legitimacy of the former alternative, the present study suggests that the 
increased PREP amplitudes observed by Obermann et al. could be related to a deficient 
inhibitory endogenous pain modulating system. 
 
Previous TN surgery 
 Our results also showed that, compared to ATN patients, a greater proportion of 
CTN patients had previously received TN surgery (see Table 2).  This phenomenon is 
probably attributable to the fact that the efficacy of neurosurgical interventions is lower 
in ATN patients than CTN patients [6;14;28;29;48].  Nevertheless, for all our variables of 
interests, the analyses showed that there was no difference between patients with and 
without previous TN surgery. 
 
Cause or consequence 
 At this point, it is difficult to know if the reduced DNIC observed in the ATN 
group represents a cause or a consequence of non-paroxystic pain episodes.  
Traditionally, it is assumed that deficient descending inhibitory circuits predate the 
development of chronic pain.  Supporting this hypothesis are recent results from 
Yarnitsky and colleagues [53] who show that inter-individual variations in DNIC strength 
predict inter-individual differences in the development of chronic post-operative pain.  
Hence it is tempting to suggest that DNIC deficits may play a causal role in non-
paroxystic pain episodes.  However, it is also possible that long-lasting noxious insults 
deplete endogenous inhibitory resources.  As a result, DNIC deficits may evolve from 
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prolonged pain [22].  Clearly, future research is essential to better understand the link that 
exists between chronic pain conditions and the functional integrity of pain modulating 
systems. 
 
Increased CPT pain scores 
 A finding somewhat more unexpected was that CTN and ATN patients had higher 
pain scores during CPT than healthy controls.  It is uncertain whether these differences 
are due to physiological or psychological factors.  For example, increased CPT pain for 
ATN patients could be attributable to reduced descending inhibition.  This explanation 
however falls short for the CTN group, in which a DNIC deficit was not observed.  
Future studies are necessary to examine this issue.  Importantly however, these group 
differences in CPT pain scores do not jeopardize the conclusions regarding DNIC 
differences, since all participants (including ATN patients) experienced pain during the 
CPT (a prerequisite for the activation of DNIC).   
 
Limitations 
An important limitation of the present study concerns the relatively small number 
of participants tested.  It is important to point out, however, that TN is a rare condition 
[41;54], making large sample size difficult to obtain.  Moreover, and despite this 
relatively small sample size, our main statistical analyses had appreciable power (1 -  = 
69%) and reached statistical significance, a situation that can be attributable to the large 
effect size observed (η2 = .17). 
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An additional limitation concerns the possible generalizability of our results.  
Because participants were recruited from the GKS clinic (which is usually reserved for 
patients who fail to respond to TN medication), one can wonder if the results obtained 
from this group of patients would also have been found in a more general TN population.  
Although we cannot completely rule out the possibility that our results are limited to 
patients who are unresponsive to medication, this appears unlikely since patients 
scheduled for GKS were not systematically unresponsive to medication.  Indeed, many 
patients agreed to GKS because they wanted to decrease drug doses and their 
accompanying side-effects.  Thus, our results are not limited to patients who fail to 
respond to TN medication.    
Finally, the absence examiner blinding in this study constitutes a possible form of 
bias.  Although enormous care was taken to prevent examiner-induced effects (e.g., use 
of identical methodology, standardized instructions and recording), one cannot 
completely exclude this possibility.  Future studies should be wary of this potential 
confound. 
 
Conclusion 
 In conclusion, our results show that ATN patients, but not CTN patients, have a 
reduced DNIC when compared to healthy controls.  These differences suggest that the 
underlying pathophysiology likely differs between CTN and ATN and that a deficit of the 
DNIC system may further contribute to the constant and diffuse pain experienced by 
patients with ATN.  The fact that ATN patients also showed the greatest degree of 
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sensitivity in body regions not innervated by the trigeminal nerve further supports the 
hypothesis of a global pain inhibitory deficit in this subgroup of patients.  
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Figures 
Figure 1. Comparisons of pain measures to thermal stimulation (mean of three 
stimulations) obtained before and after CPT.  Unlike ATN patients, healthy participants 
and CTN patients showed a reduction in pain after the CPT (** p<.01). 
 
 
Figure 2. Percentage changes between thermal pain measures obtained before and after 
CPT.  Healthy participants and CTN patients had a 21% and 16% reduction in thermal 
pain following CPT, respectively, whereas there was virtually no change for patients with 
ATN (1% decrease) (* p<.05). 
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Table 1
Patient 
number  
 
Age 
(yrs)/ 
gender 
 
Classification Affected 
side 
Affected 
territory 
Medications 
(daily doses) 
 
 
1 
 
85/ F 
 
ATN 
 
Right 
 
V2, V3 
 
 
 
 
Pregabalin 150 mg BID 
Celecoxib 100 mg BID 
Carbamazepine 200 mg BID 
 
2 
 
81/ F ATN Left V2, V3 
 
Oxcarbazepine 50 mg BID 
 
6 53/ F ATN Left V1, V2, V3 Pregabalin 75 mg BID 
 
8 62/ M ATN Left V2, V3 
 
Oxcarbazepine 300 mg QID 
 
13 39/ F ATN Left V1 
 
Tramadol/acetaminophen 75 / 650 
mg QID 
Hydromorphone (controlled release) 
3 mg BID 
 
14 50/ M ATN Right V2, V3 
 
Oxcarbazepine 600 mg BID 
Amitriptyline 20 mg QD 
 
 
15 
 
72/ M 
 
ATN 
 
Right 
 
V2, V3 
 
 
Carbamazepine 200 mg TID 
Gabapentine 100 mg QID 
 
18 71/ F ATN Left V3 
 
Gabapentine 600 mg TID 
 
19 72/ M ATN Right V3 
 
Pregabalin 75 mg BID 
 
20 72/ M ATN Right V1, V2, V3 
 
Prednisone 5 mg QD 
Carbamazepine CR 200 mg TID 
Acetylsalicylic acid 160 mg QD 
Acetaminophen 500 mg QID 
Oxycodone 5 mg QID PRN 
 
21 53/ M ATN Left V2 
 
Gabapentine 300 mg TID 
 
22 53/ M ATN Left V1, V2 
 
Topiramate 100 mg BID 
Baclofen 20 mg TID 
Methadone 5 mg QID 
Duloxetine 60 mg QD 
Quetiapine 200 mg QD 
 
26 
 
76/ M ATN Left V3 
 
Oxcarbazepine 600 mg BID 
Acetylsalicylic acid  325 mg QD 
Phenytoin 100 mg TID 
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Patient 
number  
 
Age 
(yrs)/ 
gender 
 
Classification Affected 
side 
Affected 
territory 
Medications 
(daily doses) 
 
 
27 
 
 
76/ M 
 
ATN 
 
Left 
 
V1, V2, V3 
 
 
Carbamazepine 600 mg BID 
 
3 67/ M CTN Left V2 
 
Gabapentine 1200 mg BID 
Pregabalin 300 mg BID 
Naproxen 500 mg PRN 
 
4 69/ M CTN Right V2, V3 
 
Pregabalin 150 mg BID 
 
5 64/ M CTN Left V1 
 
Gabapentine 400 mg TID 
Baclofen 10 mg QID 
Pramipexole 0.25 mg QD 
 
7 78/ M CTN Left V2 Oxcarbazepine 150 mg BID 
9 57/ F CTN Right V2, V3 
 
Carbamazepine 200 mg BID 
 
10 66/ M CTN Left V2, V3 
 
Gabapentine 300 mg QID 
Carbamazepine 200 mg TID 
Topiramate 100 mg TID 
 
11 70/ F CTN Right V1, V2 
 
Oxcarbazepine 300 mg BID 
 
12 59/ M CTN Right V2 
 
Carbamazepine 1200 mg TID 
Acetylsalicylic acid 325 mg QD 
 
16 80/ F CTN Right V3 
 
Carbamazepine 300 mg TID 
Gabapentine 400 mg QD 
 
17 58/ M CTN Right V2 Carbamazepine 400 mg QID 
 
23 65/ M CTN Left V1 
 
Oxcarbazepine 600 mg TID 
 
24 59/ M CTN Right V2, V3 
 
 
Oxcarbazepine 900 mg BID 
Baclofen 20 mg TID 
 
25 42/ F CTN Left V2 Oxcarbazepine 300 mg TID 
28 
 
56/ F CTN Right V1, V2 Carbamazepine 500 mg BID 
Amitriptyline 20 mg QD 
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Table 2 
  
Healthy 
(n=14) 
 
 
CTN 
(n=14) 
 
ATN 
(n=14) 
 
p-value 
 
Gender 
 
7 males 9 males 9 males .67 
Age 
 
64.6 ± 9.4 63.6 ± 9.6 65.4 ± 13.6 .78 
Time since 
onset of 
symptoms (yrs) 
 
- 6.1 ± 5.3 8.6 ± 7.5 .51 
Side affected 
 
- 6 left 9 left .45 
Territory 
affected 
- V1 = 2 
V2 = 5 
V3 = 1 
V1, V2 = 2 
V2, V3 = 4 
 
V1 = 1 
V2 = 1 
V3 = 3 
V1, V2 = 1 
V2, V3 = 5 
V1, V2, V3= 3 
 
.19 
Previous TN 
surgery 
 
- 7 1 <.05 
MPQ 
 
- 44.2 ± 12.8 39.5 ± 18.3 .51 
MPQ = McGill Pain Questionnaire (Pain Rating Index)[32] 
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Table 3 
 
 Facial pain scores 
 
 
  
46 ºC 
 
 
47 ºC 
 
48 ºC 
 
 
p-value 
 
CTN 
 
47 ± 29 
 
 
62 ± 25 
 
66 ± 25 
 
<.001 
ATN 46 ± 25 
 
56 ± 28 63 ± 28 <.001 
Healthy 34 ± 21 
 
38 ± 24 48 ± 25 <.01 
 
p-value 
 
 
.26 
 
.03 
 
.11 
 
Marchand 25 
References 
 
 [1]  Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with 
chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch 
Intern Med 2000 Jan 24;160(2):221-7. 
 [2]  Adams CB. Microvascular compression: an alternative view and hypothesis. J 
Neurosurg 1989 Jan;70(1):1-12. 
 [3]  Baechli H, Gratzl O. Microvascular decompression in trigeminal neuralgia with 
no vascular compression. Eur Surg Res 2007;39(1):51-7. 
 [4]  Balasubramaniam R, de LR, Zhu H, Nickerson RB, Okeson JP, Carlson CR. 
Prevalence of temporomandibular disorders in fibromyalgia and failed back 
syndrome patients: a blinded prospective comparison study. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod 2007 Aug;104(2):204-16. 
 [5]  Bouhassira D, Bing Z, Le BD. Studies of the brain structures involved in diffuse 
noxious inhibitory controls: the mesencephalon. J Neurophysiol 1990 
Dec;64(6):1712-23. 
 [6]  Brisman R. Gamma knife surgery with a dose of 75 to 76.8 Gray for trigeminal 
neuralgia. J Neurosurg 2004 May;100(5):848-54. 
 [7]  Cole CD, Liu JK, Apfelbaum RI. Historical perspectives on the diagnosis and 
treatment of trigeminal neuralgia. Neurosurg Focus 2005;18(5):E4. 
 [8]  Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, 
Zakrzewska JM. AAN-EFNS guidelines on trigeminal neuralgia management. 
Eur J Neurol 2008 Oct;15(10):1013-28. 
 [9]  Dao TT, Reynolds WJ, Tenenbaum HC. Comorbidity between myofascial pain of 
the masticatory muscles and fibromyalgia. J Orofac Pain 1997;11(3):232-41. 
 [10]  Ferreira PH, Ferreira ML, Hodges PW. Changes in recruitment of the abdominal 
muscles in people with low back pain: ultrasound measurement of muscle 
activity. Spine 2004 Nov 15;29(22):2560-6. 
 [11]  Fields H, Basbaum A, Heinricher MM. Central nervous system mechanisms of 
pain modulation. In: McMahon SB, Koltzenburg M, editors. Wall and Melzack's 
Textbook of Pain. 5th ed. China: Elsevier Churchill Livingstone; 2006. p. 125-42. 
 [12]  Forssell H, Tenovuo O, Silvoniemi P, Jaaskelainen SK. Differences and 
similarities between atypical facial pain and trigeminal neuropathic pain. 
Neurology 2007 Oct 2;69(14):1451-9. 
 [13]  Fromm GH, Chattha AS, Terrence CF, Glass JD. Role of inhibitory mechanisms 
in trigeminal neuralgia. Neurology 1981 Jun;31(6):683-7. 
Marchand 26 
 [14]  Gorgulho A, De Salles AA, McArthur D, Agazaryan N, Medin P, Solberg T, 
Mattozo C, Ford J, Lee S, Selch MT. Brainstem and trigeminal nerve changes 
after radiosurgery for trigeminal pain. Surg Neurol 2006 Aug;66(2):127-35. 
 [15]  Graven-Nielsen T, Babenko V, Svensson P, Arendt-Nielsen L. Experimentally 
induced muscle pain induces hypoalgesia in heterotopic deep tissues, but not in 
homotopic deep tissues. Brain Res 1998 Mar 23;787(2):203-10. 
 [16]  Gronseth G, Cruccu G, Alksne J, Argoff C, Brainin M, Burchiel K, Nurmikko T, 
Zakrzewska JM. Practice parameter: the diagnostic evaluation and treatment of 
trigeminal neuralgia (an evidence-based review): report of the Quality Standards 
Subcommittee of the American Academy of Neurology and the European 
Federation of Neurological Societies. Neurology 2008 Oct 7;71(15):1183-90. 
 [17]  Hagberg C, Hagberg M, Kopp S. Musculoskeletal symptoms and psychosocial 
factors among patients with craniomandibular disorders. Acta Odontol Scand 
1994 Jun;52(3):170-7. 
 [18]  Hardy DG, Rhoton AL, Jr. Microsurgical relationships of the superior cerebellar 
artery and the trigeminal nerve. J Neurosurg 1978 Nov;49(5):669-78. 
 [19]  Headache Classification Commitee of the International Headache Society. The 
International Classification of Headache Disorders: 2nd edition. Cephalalgia 
2004;24 Suppl 1:9-160. 
 [20]  Ishikawa M, Nishi S, Aoki T, Takase T, Wada E, Ohwaki H, Katsuki T, Fukuda 
H. Operative findings in cases of trigeminal neuralgia without vascular 
compression: proposal of a different mechanism. J Clin Neurosci 2002 
Mar;9(2):200-4. 
 [21]  Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia 
is related to a deficit of endogenous pain inhibition. Pain 2005 Mar;114(1-2):295-
302. 
 [22]  Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious 
conditioning stimulation in patients with painful osteoarthritis before, but not 
following, surgical pain relief. Pain 2000 Oct;88(1):69-78. 
 [23]  Kress B, Schindler M, Rasche D, Hahnel S, Tronnier V, Sartor K. [Trigeminal 
neuralgia: how often are trigeminal nerve-vessel contacts found by MRI in normal 
volunteers]. Rofo 2006 Mar;178(3):313-5. 
 [24]  Lariviere M, Goffaux P, Marchand S, Julien N. Changes in pain perception and 
descending inhibitory controls start at middle age in healthy adults. Clin J Pain 
2007 Jul;23(6):506-10. 
 [25]  Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in 
fibromyalgia. Clin J Pain 1997 Sep;13(3):189-96. 
Marchand 27 
 [26]  Lautenbacher S, Roscher S, Strian F. Inhibitory effects do not depend on the 
subjective experience of pain during heterotopic noxious conditioning stimulation 
(HNCS): a contribution to the psychophysics of pain inhibition. Eur J Pain 
2002;6(5):365-74. 
 [27]  Le Bars D., Dickenson AH, Besson JM. Diffuse noxious inhibitory controls 
(DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979 
Jun;6(3):283-304. 
 [28]  Li ST, Pan Q, Liu N, Shen F, Liu Z, Guan Y. Trigeminal neuralgia: what are the 
important factors for good operative outcomes with microvascular decompression. 
Surg Neurol 2004 Nov;62(5):400-4. 
 [29]  Maesawa S, Salame C, Flickinger JC, Pirris S, Kondziolka D, Lunsford LD. 
Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal 
neuralgia. J Neurosurg 2001 Jan;94(1):14-20. 
 [30]  Maixner W, Fillingim R, Booker D, Sigurdsson A. Sensitivity of patients with 
painful temporomandibular disorders to experimentally evoked pain. Pain 1995 
Dec;63(3):341-51. 
 [31]  McLaughlin MR, Jannetta PJ, Clyde BL, Subach BR, Comey CH, Resnick DK. 
Microvascular decompression of cranial nerves: lessons learned after 4400 
operations. J Neurosurg 1999 Jan;90(1):1-8. 
 [32]  Melzack R. The McGill Pain Questionnaire: major properties and scoring 
methods. Pain 1975 Sep;1(3):277-99. 
 [33]  Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends 
Pharmacol Sci 2006 Jul;27(7):348-54. 
 [34]  Millan MJ. Descending control of pain. Prog Neurobiol 2002 Apr;66(6):355-474. 
 [35]  Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, 
Lautenbacher S, Moller JC. Pain sensitivity and descending inhibition of pain in 
Parkinson's disease. J Neurol Neurosurg Psychiatry 2009 Jan;80(1):24-8. 
 [36]  Obermann M, Yoon MS, Ese D, Maschke M, Kaube H, Diener HC, Katsarava Z. 
Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. 
Neurology 2007 Aug 28;69(9):835-41. 
 [37]  Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced 
diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain 2009 Apr 7. 
 [38]  Rhodus NL, Fricton J, Carlson P, Messner R. Oral symptoms associated with 
fibromyalgia syndrome. J Rheumatol 2003 Aug;30(8):1841-5. 
 [39]  Rose FC. Trigeminal neuralgia. Arch Neurol 1999 Sep;56(9):1163-4. 
Marchand 28 
 [40]  Sandrini G, Rossi P, Milanov I, Serrao M, Cecchini AP, Nappi G. Abnormal 
modulatory influence of diffuse noxious inhibitory controls in migraine and 
chronic tension-type headache patients. Cephalalgia 2006 Jul;26(7):782-9. 
 [41]  Scrivani SJ, Mathews ES, Maciewicz RJ. Trigeminal neuralgia. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endod 2005 Nov;100(5):527-38. 
 [42]  Shaya M, Jawahar A, Caldito G, Sin A, Willis BK, Nanda A. Gamma knife 
radiosurgery for trigeminal neuralgia: a study of predictors of success, efficacy, 
safety, and outcome at LSUHSC. Surg Neurol 2004 Jun;61(6):529-34. 
 [43]  Sindou M, Howeidy T, Acevedo G. Anatomical observations during 
microvascular decompression for idiopathic trigeminal neuralgia (with 
correlations between topography of pain and site of the neurovascular conflict). 
Prospective study in a series of 579 patients. Acta Neurochir (Wien ) 2002 
Jan;144(1):1-12. 
 [44]  Sipila K, Zitting P, Siira P, Niinimaa A, Raustia AM. Generalized pain and pain 
sensitivity in community subjects with facial pain: a case-control study. J Orofac 
Pain 2005;19(2):127-32. 
 [45]  Tousignant-Laflamme Y, Page S, Goffaux P, Marchand S. An experimental 
model to measure excitatory and inhibitory pain mechanisms in humans. Brain 
Res 2008 Jul 9. 
 [46]  Turp JC, Kowalski CJ, O'Leary N, Stohler CS. Pain maps from facial pain 
patients indicate a broad pain geography. J Dent Res 1998 Jun;77(6):1465-72. 
 [47]  Tuveson B, Leffler AS, Hansson P. Time dependent differences in pain sensitivity 
during unilateral ischemic pain provocation in healthy volunteers. Eur J Pain 2006 
Apr;10(3):225-32. 
 [48]  Tyler-Kabara EC, Kassam AB, Horowitz MH, Urgo L, Hadjipanayis C, Levy EI, 
Chang YF. Predictors of outcome in surgically managed patients with typical and 
atypical trigeminal neuralgia: comparison of results following microvascular 
decompression. J Neurosurg 2002 Mar;96(3):527-31. 
 [49]  Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of 
treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008 
Sep 15;59(9):1279-98. 
 [50]  Willer JC, Bouhassira D, Le BD. [Neurophysiological bases of the 
counterirritation phenomenon:diffuse control inhibitors induced by nociceptive 
stimulation]. Neurophysiol Clin 1999 Oct;29(5):379-400. 
 [51]  Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, 
Tugwell P, Campbell SM, Abeles M, Clark P, . The American College of 
Marchand 29 
Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the 
Multicenter Criteria Committee. Arthritis Rheum 1990 Feb;33(2):160-72. 
 [52]  Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, 
Bushnell MC, Chizh BA. Fibromyalgia patients show an abnormal dopamine 
response to pain. Eur J Neurosci 2007 Jun;25(12):3576-82. 
 [53]  Yarnitsky D, Crispel Y, Eisenberg E, Granovsky Y, Ben-Nun A, Sprecher E, Best 
LA, Granot M. Prediction of chronic post-operative pain: pre-operative DNIC 
testing identifies patients at risk. Pain 2008 Aug 15;138(1):22-8. 
 [54]  Zakrzewska JM. Trigeminal neuralgia. Prim Dent Care 1997 Jan;4(1):17-9. 
 [55]  Zakrzewska JM. Diagnosis and differential diagnosis of trigeminal neuralgia. Clin 
J Pain 2002 Jan;18(1):14-21. 
 [56]  Zakrzewska JM, Jassim S, Bulman JS. A prospective, longitudinal study on 
patients with trigeminal neuralgia who underwent radiofrequency 
thermocoagulation of the Gasserian ganglion. Pain 1999 Jan;79(1):51-8. 
 
 
